Lexicon Pharmaceuticals Inc（LXRX）资讯与事件LXRXLexicon Pharmaceuticals Inc

Major Averages Broadly Lower as Oil Prices Surge Over 3%

The major averages were broadly lower to start the week, with oil prices surging over 3% after President Donald Trump rejected conditions for a ceasefire presented by Iran. Treasury yields are also rising while several AI stocks, including AMD and Micron, were slipping.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Nvidiahas launched an agent safety platform following recent security incidents and authorized an additional $150B under its existing share repurchase programMongoDBCEO Chirantan Desai has left the company to take on the role as Meta'sEnterprise Platform OfficerBoeinghas discovered a glitch to the 737 MAX software that could cause its automated navigation feature to fail, WSJ reportsBrixmorand Everview Partners agreed to acquire Slate Grocery REITfor $2.34BJana Partners is pushing Fiservto more than double planned cost reductions, Reuters reports2. WALL STREET CALLS:Royal Caribbeanupgraded to Buy at both Deutsche Bank and BofARobloxdowngraded to Underperform at JefferiesPark Hotelsupgraded to Strong Buy from Market Perform at Raymond JamesPepsiCodowngraded to Hold from Buy at Deutsche BankSweetgreenupgraded to Overweight at Wells Fargo3. AROUND THE WEB:Airbusand Leonardoare investigating a coatings defect affecting about 500 A321neo jets, Reuters reportsUber'sKenyan safari business is facing resistance from local guides, WSJ saysFugazi Research said in a new research report that the firm considers Greenland Energy'sstock "uninvestable" at "any price above zero"A EUR 10.3B bid by BASFfor Evonikhas been rejected as too low towarrant negotiations, setting up a potential takeover battle as Evonik pursues restructuring and divestitures amid broader consolidation in Europe's challenged chemicals industry, FT reportsMetaVR Glasses is the product Apple'sVision Pro should have been, Bloomberg says4. MOVERS:Kodiak Sciencesgains after announcing its Phase 3 DAYBREAK study met its primary endpointsBurford Capitalincreases after issuing comments related to the patent matter between Apple and TactionLexiconhigher after Cantor Fitzgerald initiated coverage of the stock with an Overweight ratingGold Fieldsfalls in New York after announcing its offer was rejected by Northern Star Resources boardNubanklower in New York after Bloomberg reported the company is in talks to acquire Monzo Bank for GBP 8B - GBP 10B5. EARNINGS/GUIDANCE:Zymeworksprovided guidance for FY26NetSol Technologiesreported Q4 results, with EPS and revenue higher year-over-yearGray Mediaannounced its outlook for Q3Kandi Technologiesreported results for H1, with EPS and revenue higher year-over-yearVestisreaffirmed its guidance for FY26INDEXES:Near midday, the Dow was down 372.37, or 0.72%, to 51,456.25, the Nasdaq was down 251.04, or 0.93%, to 26,817.68, and the S&P 500 was down 61.51, or 0.79%, to 7,681.90.

Lexicon Announces Heart Failure Drug Study Results

Lexicon announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety of sotagliflozin across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure. The data, which were presented at ESC Congress in Munich, Germany and simultaneously published in JACC: Heart Failure, demonstrated that the results of sotagliflozin treatment were maintained regardless of baseline systolic blood pressure. Among patients with baseline systolic blood pressure as low as 100 mmHg, treatment with sotagliflozin was associated with a reduction in cardiovascular death and heart failure-related events, without an increase in hypotension or acute kidney injury. Among patients with a baseline SBP less than110 mmHg, those randomized to sotagliflozin experienced a reduction in total occurrences of cardiovascular deaths and HF-related events. These data suggest efficacy of sotagliflozin in even the lowest SBP stratum. There was no difference in the incidence of adverse events of hypotension between treatment groups or AKI. Additionally, patients with a baseline SBP greater than or equal to 110 mmHg also experienced a reduction in total occurrences of cardiovascular deaths and HF-related events.

Lexicon Earns $10M Milestone Payment from Novo Nordisk

Lexicon (LXRX) announced that it has earned a third $10M milestone payment in 2026 from Novo Nordisk (NVO) following the achievement of a patient dosing milestone in the ongoing Phase 1 clinical development program for LX9851. LX9851 is being advanced by Novo Nordisk under the companies' exclusive worldwide license agreement signed in 2025. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. With the achievement of this milestone, Lexicon has now earned $75M of the $1B in potential upfront, development, regulatory and commercial milestone payments available under its collaboration with Novo Nordisk. In addition, Lexicon is entitled to receive tiered royalties on future net sales of LX9851.